Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Ovarian epithelial cancer
Stage/Subtype:  recurrent ovarian epithelial cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 95 for your search:
Start Over
Trametinib in Treating Patients with Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: GOG-0281, NCI-2014-00629, NCT02101788
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 8109-002, NCI-2011-00940, EC-FV-06, NCT01170650
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR100983, NCI-2013-01419, 2012-004808-34, ET743OVC3006, NCT01846611
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ARRAY-162-311, NCI-2013-00934, 2013-000277-72, NCT01849874
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC0861, NCI-2011-00312, 09-000742, CDR0000657976, MAYO-MC0861, 8329, NCT01012817
Cediranib Maleate and Olaparib in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 09-293, NCI-2012-02938, DFCI IRB 09-293, NCI-2010-01329, NCI-2013-00578, NCT01115829, 8348, NCT01116648
Vaccine Therapy in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC29810, NCI-2011-00285, NCT01312389
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Pegylated Liposomal Doxorubicin Hydrochloride and Nintedanib in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, Fallopian Tube, or Recurrent Metastatic Endometrial Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GYN10-149, NCI-2012-02106, 1011004095, 1103-09, NCT01485874
Fenretinide/Fenretinide Lipid Matrix and Ketoconazole in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SPOC-2011-001, NCI-2012-00354, NCT01550692, NCT01535157
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADP-0011-001, NCI-2015-00728, 230612, NCT01567891
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
A Study of LY2228820 for Recurrent Ovarian Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12517, NCI-2012-01426, I1D-MC-JIAE, NCT01663857
Paclitaxel and Vascular-Targeting Gene Therapeutic VB-111 in Treating Patients with Recurrent Uterine, Ovarian, and Fallopian Tube Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 11-418, NCI-2013-00628, NCT01801215, VB-111-157, NCT01711970
GSK2141795, Dabrafenib, and Trametinib in Treating Patients with Stage IIIC-IV Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1221, NCI-2013-01320, SWOG-S1221, NCT01902173
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 21
Trial IDs: M18-005, NCI-2014-01397, NCT01952249
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GYN-064, NCI-2013-01416, 13-028, NCT01962948
PARP inhibitor BMN-673 in Treating Patients with Advanced Solid Tumors and BRCA Mutations
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-C-0015, NCI-2013-02371, 09-25-0099, 140015, P131220, P9510_A08PAMDREVW01, 9510, NCT01989546
MV-NIS Infected Mesenchymal Stem Cells in Treating Patients with Recurrent Ovarian Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1266, NCI-2014-00016, NCT02068794
Erismodegib and Paclitaxel in Treating Patients with Recurrent Ovarian Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: UAB 1357, NCI-2015-01335, F140214007, NCT02195973
Olaparib and mTOR Kinase Inhibitor AZD2014 or AKT Inhibitor AZD5363 in Treating Patients with Recurrent Endometrial, Triple Negative Breast, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0784, NCI-2014-01973, NCT02208375
Start Over